Recon: Moderna sets COVID vax price at $130/shot; Bancel defends decision at Senate hearing

• Moderna to Price Its Covid-19 Vaccine at $130 a Dose (Wall Street Journal)
• Delays in reporting led FDA to late cancer warning on breast implants, advocates say (Medtech Dive)
• Moderna CEO defends price of COVID shot at Senate hearing (Healthcare Dive)
• 'Banding together': 50 female biotech executives lay out plans for board diversity, new companies and mentoring founders (Endpoints News)
• Social media patient influencers ‘dancing in the gray’ of pharma marketing, more clarity needed, researcher says (Endpoints News)
• A Milestone Moment For Pharmacogenomics: US FDA Ready To Drop ‘Voluntary’ Program (Pink Sheet)
• Electronic Records: US FDA Updates Guidelines On Use In Clinical Investigations (Pink Sheet)

• European Commission Proposes First “Master UDI-DI” - For Contact Lenses (Medtech Insight)
• Australia To Seek Stakeholder Input On Terms Of HTA Review (Pink Sheet)
• Switzerland: US FDA’s Medtech Can Bridge Innovation Gap Left By MDR (Medtech Insight)
• EU IVD Regulation Delaying Clinical Trials Using Diagnostics (Medtech Insight)
• China Grants First mRNA COVID Vaccine Approval To Homegrown Latecomer (Pink Sheet)

• Sanofi, Regeneron boast PhIII win with Dupixent in COPD, clearing first bar for expansion (Endpoints News) (Reuters)
• ‘In A Word, Complicated’ – AAM’s Burton Talks US Biosimilars (Pink Sheet)
• Three People Have Died From Bacteria Outbreak Linked to Eye Drops (Wall Street Journal)
• Roche, Lilly team on test for early detection of Alzheimer’s (Medtech Dive)
• FDA advisers support conditional clearance of Biogen’s ALS drug (Biopharma Dive)
• Biohaven strikes a deal to take TYK2 drugs in a new direction (Biopharma Dive)
• At EpiBiologics, a pair of Genentech alumni wants to make next-gen protein degraders (Biopharma Dive)
• A biotech stumbles in its bid to challenge Novo’s obesity drug (Biopharma Dive)
• Novo partners with Dewpoint to mine an emerging field for new drugs (Biopharma Dive)
• FDA warns Procter & Gamble over NyQuil label's ingredient listings (Endpoints News)
• Genentech to stop commercial manufacturing at California headquarters (Endpoints News)
• Drug developer 89Bio soars as NASH drug succeeds in mid-stage study (Reuters)
• US FDA grants accelerated approval for Incyte's skin cancer therapy (Reuters)

• NuVasive shareholders expected to ‘begrudgingly’ back Globus’ $3.1B takeover amid lack of other bidders (Medtech Dive)
• Medtronic, NVIDIA to combine forces on AI devices, allowing users to create new software (Medtech Dive)
• FDA rejects AbbVie's infusion therapy for Parkinson's, requests more info on pump device (Endpoints News)
• Huma Secures EU MDR Approval For Medtech Software That Can Be Used In Any Disease (Medtech Insight)
• DOJ Files Preliminary Injunction Against Neoprene Manufacturer (Medtech Insight)
• How Innovative UTI Diagnostics Can Help Combat Antibiotic Resistance (Medtech Insight)
• Asensus Surgical Gets Pediatric Indication for Robotic Laparoscopic Device (FDAnews)
• FDA Updates its List of Medical Devices in Short Supply (FDAnews)

• FTC wades into dispute between Supernus, generic competitor (Biopharma Dive) (Endpoints News)
• U.S. government again rejects call to seize Xtandi rights (Biopharma Dive)
• Rising Rate of Drug Shortages Is Framed as a National Security Threat (New York Times) (Endpoints News)
• PhRMA calls for more diverse infrastructure upgrades to US emergency trials framework (Endpoints News)
• J&J to seek U.S. Supreme Court review on unit's bankruptcy (Reuters)
• The much-maligned ‘quality-adjusted life year’ is a vital tool for health care policy (STAT+)
• Sanofi Tells Justices It Couldn't Give Away EpiPen Rival (Law360)